| Literature DB >> 36231177 |
Dominika Skolmowska1, Dominika Głąbska1.
Abstract
In order to maintain an adequate iron status in young women, effective dietary interventions should provide sufficient amounts of iron in everyday meals and improve the bioavailability of non-heme iron by providing vitamin C. While some intervention studies administering products rich in vitamin C in conjunction with iron sources showed improved iron status, it is unknown whether a separate administration of products rich in iron and vitamin C may be a successful strategy as well. The aim of this study was to assess the effectiveness of dietary intervention with iron and vitamin C administered separately in improving iron status in young women to prevent iron deficiency anemia. The study was conducted in a group of 29 women aged 18-30, and an 8-week dietary intervention was performed. Study participants with an adequate iron status received 50 g of iron-fortified oat flakes (as a source of non-heme iron) with breakfast and 200 mL of orange juice (as a source of vitamin C) in the second part of the day. Iron status was analyzed based on red blood cells, hemoglobin, hematocrit, serum ferritin, and serum iron, and it was assessed at baseline, after 4 weeks, and after 8 weeks of the intervention. The intakes of iron, vitamin C, and folate were controlled throughout the study period, and menstrual blood loss was estimated. After 8 weeks of intervention, statistically significant differences compared with baseline were observed only for hematocrit, as its level after 8 weeks of intervention was higher than the baseline (p = 0.0491). Comparing subsamples within the dietary intervention considered effective and ineffective for red blood cell levels, it was indicated that lower baseline vitamin C intake may result in a more effective dietary intervention (p = 0.0231). Comparing subsamples within the dietary intervention considered effective and ineffective for hemoglobin, hematocrit, iron, and serum ferritin levels, it was indicated that higher baseline levels of hemoglobin (p = 0.0143), hematocrit (p = 0.0497), iron (p = 0.0101), and serum ferritin (p = 0.0343) respectively may result in a more effective dietary intervention. It was concluded that dietary intervention with iron and vitamin C administered separately may be effective in improving iron status in young women to prevent iron deficiency anemia. It may be concluded that in the studied group, a better baseline iron status and lower baseline vitamin C intake may result in a more effective dietary intervention with iron and vitamin C administered separately to improve iron status in young women.Entities:
Keywords: dietary intervention; iron absorption; iron status; iron-fortified products; non-heme iron; plant-based dietary intervention; vitamin C; young women
Mesh:
Substances:
Year: 2022 PMID: 36231177 PMCID: PMC9564482 DOI: 10.3390/ijerph191911877
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
The baseline characteristics of the participants of the study (n = 29).
| Mean ± SD | Median | Min | Max | |
|---|---|---|---|---|
| Age (years) | 24.5 ± 2.0 | 24.0 | 21.0 | 29.0 |
| Body weight (kg) | 60.2 ± 7.1 | 60.3 | 48.2 | 74.7 |
| Height (cm) | 165.3 ± 5.0 | 165.0 | 156.0 | 175.0 |
| BMI (kg/m2) | 22.0 ± 2.5 | 22.1 | 18.0 | 29.4 |
| Fat mass (%) | 27.7 ± 5.8 | 27.7 | 15.5 | 40.1 |
| Total body water (%) | 52.9 ± 4.2 | 52.9 | 43.9 | 61.8 |
| Muscle mass (%) | 68.7 ± 5.5 | 68.8 | 57.0 | 80.3 |
| Menstrual blood loss (mL) | 55.1 ± 28.3 | 48.5 * | 16.0 | 112.0 |
* nonparametric distribution (verified using Shapiro–Wilk test).
Baseline dietary intake of the participants of the study (n = 29).
| Mean ± SD | Median | Min | Max | |
|---|---|---|---|---|
| Iron (mg/day) | 11.49 ± 4.72 | 10.29 | 3.89 | 20.48 |
| Animal iron (mg/day) | 2.36 ± 1.49 | 2.53 | 0.0 | 5.25 |
| Plant iron (mg/day) | 9.13 ± 4.97 | 8.78 | 2.47 | 20.48 |
| Heme iron (mg/day) | 0.94 ± 0.60 | 1.01 | 0.00 | 2.10 |
| Non-heme iron (mg/day) | 10.54 ± 4.77 | 9.33 | 3.32 | 20.48 |
| Vitamin C (mg/day) | 105.39 ± 64.42 | 77.50 * | 32.86 | 240.71 |
| Folate (µg/day) | 248.90 ± 127.29 | 214.99 * | 100.28 | 635.73 |
* nonparametric distribution (verified using Shapiro–Wilk test).
The iron status of the participants of the study (n = 29), accompanied by the other hematological parameters, throughout the study period.
| Variables—Baseline Level | t0—at Baseline | t4—after 4 Weeks of Intervention | t8—after 8 Weeks of Intervention | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median (Min–Max) | Mean ± SD | Median (Min–Max) | Mean ± SD | Median (Min–Max) | ||||
| RBC | 4.43 ± 0.34 | 4.50 (3.60–5.00) | 4.50 ± 0.29 | 4.40 * (4.00–5.20) | 4.51 ± 0.32 | 4.40 (4.00–5.20) | 0.0299 | 0.8191 | 0.0580 |
| Hb | 13.1 ± 0.8 | 12.9 * (11.0–14.1) | 13.3 ± 0.7 | 13.1 (12.1–14.4) | 13.3 ± 0.8 | 13.3 (11.7–15.4) | 0.1059 | 0.5532 | 0.0619 |
| Ht | 39.7 ± 2.4 | 40.0 (33.0–43.0) | 40.3 ± 1.9 | 40.0 (37.0–44.0) | 40.5 ± 2.3 | 40.0 (36.0–46.0) | 0.0785 | 0.7262 | 0.0491 |
| Fe | 95.5 ± 45.6 | 95.6 (24.7–208.8) | 85.3 ± 40.1 | 76.7 * (40.2–217.5) | 93.8 ± 50.10 | 92.8 (25.7–215.1) | 0.1919 | 0.3761 | 0.8372 |
| SF | 36.7 ± 25.8 | 33.3 * (7.1–119.0) | 28.3 ± 22.2 | 20.8 * (9.1–121.0) | 32.8 ± 28.6 | 29.5 * (7.55–156.0) | 0.0128 | 0.0189 | 0.3290 |
| MCV | 89.8 ± 3.5 | 90.0 (81.0–95.0) | 89.8 ± 4.0 | 90.0 (81.0–96.0) | 89.8 ± 4.0 | 89.0 (81.0–97.0) | 0.9250 | 1.0000 | 0.9447 |
| MCH | 29.6 ± 1.7 | 30.0 * (26.0–32.0) | 29.5 ± 1.7 | 30.0 * (26.0–32.0) | 29.6 ± 1.7 | 30.0 * (26.0–32.0) | 0.5751 | 0.4446 | 0.8139 |
| MCHC | 32.9 ± 0.9 | 32.9 (30.6–34.5) | 32.8 ± 0.8 | 32.9 (31.5–34.3) | 32.9 ± 0.8 | 32.9 (31.4–34.3) | 0.5910 | 0.4608 | 0.8068 |
| Plt | 250.6 ± 63.7 | 242.0 (42.0–370.0) | 255.9 ± 59.7 | 244.0 (146.0–401.0) | 255.2 ± 48.8 | 257.0 (146.0–344.0) | 0.4919 | 0.9029 | 0.5386 |
| WBC | 6.11 ± 1.50 | 5.50 * (3.50–9.80) | 6.59 ± 2.33 | 5.90 * (4.10–16.10) | 6.11 ± 1.19 | 5.90 * (3.80–9.00) | 0.2106 | 0.4167 | 0.3381 |
* nonparametric distribution (verified using Shapiro–Wilk test; p ≤ 0.05). RBC—red blood cells (mln/µL); Hb—hemoglobin (g/dL); Ht—hematocrit (%); Fe—serum iron (µg/dL); SF—serum ferritin (ng/mL); MCV—mean corpuscular volume (%); MCH—mean corpuscular hemoglobin (pg); MCHC—mean corpuscular hemoglobin concentration (g/dL); Plt—platelets (109/L); WBC—white blood cells (109/L).
The comparison of the baseline characteristics of the subsamples (red blood cells level, dietary intake, and menstrual blood loss) in subsamples stratified by the effectiveness of dietary intervention assessed for red blood cells level after 4 and 8 weeks.
| Subsamples stratified by effectiveness assessed after 4 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline RBC | 4.48 ± 0.36 | 4.40 (4.00–5.20) | 4.58 ± 0.21 | 4.55 (4.30–4.90) | 0.4917 | |
| Iron (mg) | 11.74 ± 4.61 | 10.82 (3.89–19.57) | 10.19 ± 5.14 | 10.11 (3.89–20.48) | 0.6435 | |
| Animal iron (mg) | 2.17 ± 1.49 | 1.80 (0.16–5.25) | 2.32 ± 1.46 | 1.98 (0.00–5.25) | 0.2769 | |
| Plant iron (mg) | 9.57 ± 4.69 | 9.74 (2.47–19.41) | 8.21 ± 5.38 | 7.39 * (2.47–20.48) | 0.3414 | |
| Heme iron (mg) | 0.87 ± 0.60 | 0.72 (0.06–2.10) | 0.93 ± 0.58 | 0.79 (0.00–2.10) | 0.2769 | |
| Non-heme iron (mg) | 10.88 ± 4.59 | 10.39 (3.32–19.51) | 9.39 ± 5.20 | 9.02 (3.32–20.48) | 0.5523 | |
| Vitamin C (mg) | 103.03 ± 60.12 | 83.93 * (32.86–240.71) | 107.85 ± 75.77 | 74.46 * (32.86–240.71) | 0.7884 | |
| Folate (µg) | 239.45 ± 130.90 | 214.99 * (100.28–635.73) | 262.76 ± 149.90 | 214.99 * (100.28–635.73) | 0.5419 | |
| Menstrual blood loss (mL) | 54.0 ± 29.7 | 44.0 (16.0–112.0) | 58.1 ± 25.7 | 50.3 (34.0–109.0) | 0.7363 | |
| Subsamples stratified by effectiveness assessed after 8 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline RBC | 4.59 ± 0.33 | 4.60 (4.10–5.20) | 4.35 ± 0.25 | 4.35 (4.00–4.80) | 0.0551 | |
| Iron (mg) | 10.87 ± 4.61 | 9.93 (3.89–19.57) | 12.66 ± 4.96 | 13.74 (5.81–20.48) | 0.3412 | |
| Animal iron (mg) | 2.10 ± 1.56 | 1.43 (0.16–5.25) | 2.87 ± 1.28 | 3.07 (0.00–4.36) | 0.1914 | |
| Plant iron (mg) | 8.77 ± 4.92 | 8.13 (2.47–19.41) | 9.79 ± 5.26 | 10.50 (3.30–20.48) | 0.6084 | |
| Heme iron (mg) | 0.84 ± 0.62 | 0.57 (0.06–2.10) | 1.15 ± 0.51 | 1.23 (0.00–1.75) | 0.1914 | |
| Non-heme iron (mg) | 10.03 ± 4.67 | 9.21 (3.32–19.51) | 11.51 ± 5.04 | 12.44 (4.80–20.48) | 0.4362 | |
| Vitamin C (mg) | 86.02 ± 55.62 | 66.07 * (32.86–240.71) | 142.18 ± 66.69 | 133.75 (57.43–240.36) | 0.0231 | |
| Folate (µg) | 230.94 ± 133.41 | 200.79 * (100.28–635.73) | 283.04 ± 113.30 | 269.22 (139.34–503.94) | 0.1484 | |
| Menstrual blood loss (mL) | 54.2 ± 29.0 | 44.0 (16.0–112.0) | 56.8 ± 28.4 | 50.5 (18.0–112.0) | 0.8213 | |
* nonparametric distribution (verified using Shapiro–Wilk test; p ≤ 0.05). RBC—red blood cells level (mln/µL).
The comparison of the baseline characteristics of the subsamples (hemoglobin level, dietary intake, and menstrual blood loss) in subsamples stratified by the effectiveness of dietary intervention assessed for hemoglobin level after 4 and 8 weeks.
| Subsamples stratified by effectiveness assessed after 4 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline Hb | 13.33 ± 0.77 | 13.30 (11.70–15.20) | 13.30 ± 0.96 | 13.10 (12.20–15.40) | 0.9410 | |
| Iron (mg) | 12.07 ± 4.48 | 12.01 (3.89–19.57) | 10.19 ± 5.27 | 7.83 (5.24–20.48) | 0.3314 | |
| Animal iron (mg) | 2.21 ± 1.52 | 2.17 (0.16–5.25) | 2.70 ± 1.45 | 2.83 (0.00–4.54) | 0.4242 | |
| Plant iron (mg) | 9.86 ± 4.62 | 10.11 (2.47–19.41) | 7.49 ± 5.61 | 4.93 * (3.30–20.48) | 0.1643 | |
| Heme iron (mg) | 0.88 ± 0.61 | 0.87 (0.06–2.10) | 1.08 ± 0.58 | 1.13 (0.00–1.82) | 0.4242 | |
| Non-heme iron (mg) | 11.19 ± 4.47 | 11.25 (3.32–19.51) | 9.11 ± 5.36 | 6.29 * (4.67–20.48) | 0.1949 | |
| Vitamin C (mg) | 106.54 ± 59.44 | 86.79 * (35.00–240.71) | 102.84 ± 78.24 | 71.43 * (32.86–240.36) | 0.7237 | |
| Folate (µg) | 246.41 ± 130.25 | 222.94 * (106.09–635.73) | 254.45 ± 127.92 | 200.79 (100.28–503.94) | 0.9812 | |
| Menstrual blood loss (mL) | 55.2 ± 30.0 | 46.5 (16.0–112.0) | 54.9 ± 25.8 | 48.5 (30.0–109.0) | 0.9825 | |
| Subsamples stratified by effectiveness assessed after 8 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline Hb | 13.56 ± 0.77 | 13.45 (12.50–15.40) | 12.78 ± 0.69 | 12.70 (11.70–13.60) | 0.0143 | |
| Iron (mg) | 11.38 ± 4.43 | 10.55 (3.89–19.57) | 11.72 ± 5.60 | 9.50 (5.81–20.48) | 0.8595 | |
| Animal iron (mg) | 2.17 ± 1.56 | 1.61 (0.16–5.25) | 2.78 ± 1.31 | 2.87 (0.00–4.36) | 0.3220 | |
| Plant iron (mg) | 9.21 ± 4.66 | 9.26 (2.47–19.41) | 8.95 ± 5.91 | 6.63 (3.30–20.48) | 0.8993 | |
| Heme iron (mg) | 0.87 ± 0.63 | 0.64 (0.06–2.10) | 1.11 ± 0.52 | 1.15 (0.00–1.75) | 0.3220 | |
| Non-heme iron (mg) | 10.51 ± 4.46 | 9.86 (3.32–19.51) | 10.61 ± 5.69 | 8.36 (4.80–20.48) | 0.9582 | |
| Vitamin C (mg) | 97.91 ± 63.65 | 69.46 * (32.86–240.71) | 122.01 ± 66.72 | 103.93 (57.14–240.36) | 0.3108 | |
| Folate (µg) | 250.75 ± 144.14 | 211.44 * (100.28–635.73) | 244.81 ± 85.65 | 230.89 (139.34–412.57) | 0.6886 | |
| Menstrual blood loss (mL) | 55.5 ± 29.0 | 44.5 (16.0–112.0) | 54.3 ± 28.4 | 49.0 (18.0–109.0) | 0.9166 | |
* nonparametric distribution (verified using Shapiro–Wilk test; p ≤ 0.05). Hb—hemoglobin level (g/dL).
The comparison of the baseline characteristics of the subsamples (hematocrit level, dietary intake, and menstrual blood loss) in subsamples stratified by the effectiveness of dietary intervention assessed for hematocrit level after 4 and 8 weeks.
| Subsamples stratified by effectiveness assessed after 4 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline Ht | 40.4 ± 2.4 | 40.0 (36.0–46.0) | 40.7 ± 1.8 | 40.5 (38.0–43.0) | 0.7973 | |
| Iron (mg) | 12.05 ± 4.89 | 10.82 (3.89–20.48) | 9.33 ± 3.56 | 8.44 (5.81–13.70) | 0.2158 | |
| Animal iron (mg) | 2.23 ± 1.61 | 1.80 (0.00–5.25) | 2.87 ± 0.79 | 2.77 (1.66–3.84) | 0.3621 | |
| Plant iron (mg) | 9.82 ± 5.18 | 9.74 (2.47–20.48) | 6.47 ± 3.11 | 5.79 (3.30–10.49) | 0.1441 | |
| Heme iron (mg) | 0.89 ± 0.65 | 0.72 (0.00–2.10) | 1.15 ± 0.32 | 1.11 (0.66–1.54) | 0.3621 | |
| Non-heme iron (mg) | 11.16 ± 4.94 | 10.39 (3.32–20.48) | 8.19 ± 3.37 | 7.38 (4.80–12.16) | 0.1786 | |
| Vitamin C (mg) | 101.68 ± 57.66 | 83.93 * (32.86–240.36) | 119.61 ± 91.10 | 74.29 * (40.00–240.71) | 0.8505 | |
| Folate (µg) | 236.25 ± 122.17 | 214.99 * (100.28–635.73) | 297.40 ± 146.64 | 234.31 (167.96–503-94) | 0.4040 | |
| Menstrual blood loss (mL) | 53.6 ± 29.1 | 44.0 * (16.0–112.0) | 61.1 ± 26.4 | 50.3 (34.0–102.0) | 0.4510 | |
| Subsamples stratified by effectiveness assessed after 8 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline Ht | 41.0 ± 2.3 | 40.5 (36.0–46.0) | 39.2 ± 1.7 | 40.0 (36.0–42.0) | 0.0497 | |
| Iron (mg) | 11.79 ± 4.81 | 10.55 (3.89–20.48) | 10.81 ± 4.74 | 7.97 * (5.81–17.18) | 0.5877 | |
| Animal iron (mg) | 2.18 ± 1.58 | 1.61 (0.00–5.25) | 2.78 ± 1.26 | 2.83 (0.20–4.36) | 0.3259 | |
| Plant iron (mg) | 9.62 ± 5.31 | 9.26 (2.47–20.48) | 8.04 ± 4.18 | 7.77 (3.30–12.90) | 0.4380 | |
| Heme iron (mg) | 0.87 ± 0.63 | 0.64 (0.00–2.10) | 1.11 ± 0.50 | 1.13 (0.08–1.75) | 0.3259 | |
| Non-heme iron (mg) | 10.92 ± 4.96 | 9.86 (3.32–20.48) | 9.70 ± 4.48 | 7.89 (4.80–15.44) | 0.5333 | |
| Vitamin C (mg) | 100.78 ± 71.09 | 66.79 * (32.86–240.71) | 115.63 ± 48.49 | 103.93 (57.14–188.93) | 0.2116 | |
| Folate (µg) | 256.40 ± 146.71 | 211.44 * (100.28–635.73) | 232.26 ± 71.67 | 230.89 (115.01–327.01) | 0.8320 | |
| Menstrual blood loss (mL) | 57.6 ± 31.5 | 44.5 (16.0–112.0) | 53.0 ± 27.5 | 48.8 (16.0–112.0) | 0.8320 | |
* nonparametric distribution (verified using Shapiro–Wilk test; p ≤ 0.05). Ht—hematocrit level (%).
The comparison of the baseline characteristics of the subsamples (iron level, dietary intake, and menstrual blood loss) in subsamples stratified by the effectiveness of dietary intervention assessed for serum iron level after 4 and 8 weeks.
| Subsamples stratified by effectiveness assessed after 4 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline Fe | 76.3 ± 51.6 | 61.1 (31.3–215.1) | 104.4 ± 47.4 | 112.0 (25.7–181.9) | 0.0835 | |
| Iron (mg) | 10.86 ± 4.63 | 10.29 (3.89–19.57) | 11.87 ± 4.87 | 11.70 (5.10–20.48) | 0.5876 | |
| Animal iron (mg) | 2.24 ± 1.02 | 2.53 (0.16–3.64) | 2.44 ± 1.74 | 2.27 (0.00–5.25) | 0.7308 | |
| Plant iron (mg) | 8.63 ± 4.94 | 8.13 (2.47–19.41) | 9.43 ± 5.10 | 9.32 (3.22–20.48) | 0.6806 | |
| Heme iron (mg) | 0.89 ± 0.41 | 1.01 (0.06–1.46) | 0.98 ± 0.70 | 0.91 (0.00–2.10) | 0.7308 | |
| Non-heme iron (mg) | 9.97 ± 4.73 | 9.21 (3.32–19.51) | 10.89 ± 4.89 | 10.75 (4.64–20.48) | 0.6213 | |
| Vitamin C (mg) | 104.49 ± 67.03 | 77.50 (35.89–240.71) | 105.94 ± 64.73 | 77.68 * (32.86–240.36) | 0.8397 | |
| Folate (µg) | 253.01 ± 161.31 | 194.89 * (109.53–635.73) | 246.39 ± 106.59 | 254.45 (100.28–503.94) | 0.6052 | |
| Menstrual blood loss (mL) | 67.4 ± 31.3 | 63.0 * (18.0–112.0) | 47.6 ± 24.2 | 38.5 (16.0–66.0) | 0.0919 | |
| Subsamples stratified by effectiveness assessed after 8 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline Fe | 116.1 ± 51.0 | 111.0 (37.5–215.1) | 69.8 ± 37.6 | 61.8 (25.7–133.2) | 0.0101 | |
| Iron (mg) | 12.72 ± 5.47 | 13.78 (3.89–20.48) | 10.16 ± 3.49 | 9.67 (5.24–16.03) | 0.1484 | |
| Animal iron (mg) | 2.34 ± 1.53 | 2.72 (0.00–4.36) | 2.39 ± 1.51 | 2.15 (0.20–5.25) | 0.9238 | |
| Plant iron (mg) | 10.39 ± 6.12 | 11.14 (2.47–20.48) | 7.77 ± 3.00 | 7.95 (3.30–13.17) | 0.1609 | |
| Heme iron (mg) | 0.93 ± 0.61 | 1.09 (0.00–1.75) | 0.96 ± 0.61 | 0.86 (0.08–2.10) | 0.9238 | |
| Non-heme iron (mg) | 11.79 ± 5.69 | 12.72 (3.32–20.48) | 9.21 ± 3.22 | 8.91 (4.67–13.93) | 0.1486 | |
| Vitamin C (mg) | 114.63 ± 72.92 | 83.93 * (35.00–240.71) | 95.49 ± 54.83 | 74.46 * (32.86–231.25) | 0.8786 | |
| Folate (µg) | 279.94 ± 138.18 | 244.99 (106.09–635.73) | 215.66 ± 109.70 | 180.15 * (100.28–503.94) | 0.1112 | |
| Menstrual blood loss (mL) | 55.6 ± 32.3 | 48.5 (16.0–109.0) | 54.6 ± 24.4 | 48.5 (26.0–112.0) | 0.9318 | |
* nonparametric distribution (verified using Shapiro–Wilk test; p ≤ 0.05). Fe—iron level (µg/dL).
The comparison of the baseline characteristics of the subsamples (serum ferritin level, dietary intake, and menstrual blood loss) in subsamples stratified by the effectiveness of dietary intervention assessed for serum ferritin level after 4 and 8 weeks.
| Subsamples stratified by effectiveness assessed after 4 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline SF | 51.4 ± 50.7 | 23.5 (12.5–156.0) | 26.9 ± 14.3 | 29.8 (7.6–50.0) | 0.3081 | |
| Iron (mg) | 11.65 ± 4.04 | 13.21 (5.10–17.18) | 11.44 ± 5.01 | 9.81 (3.89–20.48) | 0.9192 | |
| Animal iron (mg) | 3.21 ± 1.13 | 3.64 (1.14–4.36) | 2.09 ± 1.51 | 1.73 (0.00–5.25) | 0.0826 | |
| Plant iron (mg) | 8.44 ± 3.52 | 9.86 (3.96–12.82) | 9.35 ± 5.40 | 8.46 (2.47–20.48) | 0.6809 | |
| Heme iron (mg) | 1.29 ± 0.45 | 1.46 (0.46–1.75) | 0.84 ± 0.61 | 0.69 (0.00–2.10) | 0.0826 | |
| Non-heme iron (mg) | 10.36 ± 3.80 | 12.12 (4.64–15.44) | 10.60 ± 5.12 | 9.27 (3.32–20.48) | 0.9118 | |
| Vitamin C (mg) | 140.08 ± 83.87 | 149.64 (40.00–240.71) | 94.35 ± 54.72 | 74.46 (32.86–240.36) * | 0.2961 | |
| Folate (µg) | 317.37 ± 125.27 | 323.90 (186.47–503.94) | 227.12 ± 122.72 | 197.84 (100.28–635.73) * | 0.0560 | |
| Menstrual blood loss (mL) | 59.9 ± 30.7 | 49.0 (16.0–102.0) | 53.6 ± 28.1 | 46.3 (18.0–112.0)* | 0.5751 | |
| Subsamples stratified by effectiveness assessed after 8 weeks |
|
|
|
| ||
|
|
|
|
| |||
| Baseline SF | 43.4 ± 36.2 | 35.4 (12.5–156.0) | 23.0 ± 14.3 | 17.5 (7.6–50.0) | 0.0343 | |
| Iron (mg) | 11.61 ± 4.02 | 12.01 (5.10–17.75) | 11.37 ± 5.44 | 9.70 (3.89–20.48) | 0.8938 | |
| Animal iron (mg) | 2.80 ± 1.35 | 2.85 (0.65–4.54) | 1.95 ± 1.54 | 1.66 (0.00–5.25) | 0.1275 | |
| Plant iron (mg) | 8.81 ± 4.22 | 9.80 (3.22–17.10) | 9.42 ± 5.71 | 8.13 (2.47–20.48) | 0.7478 | |
| Heme iron (mg) | 1.12 ± 0.54 | 1.14 (0.26–1.82) | 0.78 ± 0.62 | 0.66 (0.00–2.10) | 0.1275 | |
| Non-heme iron (mg) | 10.49 ± 4.05 | 11.25 (4.64–17.49) | 10.59 ± 5.50 | 9.21 (3.32–20.48) | 0.9565 | |
| Vitamin C (mg) | 104.55 ± 70.77 | 66.43 * (35.00–240.71) | 106.17 ± 60.39 | 89.64 (32.86–240.36) | 0.5557 | |
| Folate (µg) | 265.97 ± 113.43 | 239.45 (106.09–503.94) | 232.97 ± 141.04 | 186.30 * (100.28–635.73) | 0.2301 | |
| Menstrual blood loss (mL) | 57.3 ± 30.8 | 46.8 (16.0–112.0) | 53.1 ± 26.7 | 52.0 (18.0–109.0) | 0.7027 | |
* nonparametric distribution (verified using Shapiro–Wilk test; p ≤ 0.05). SF—serum ferritin level (ng/mL).